Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE

Abstract Recently, for many health economics researchers, empirical estimation of the monetary valuation of a quality-adjusted life year (QALY) has become an important endeavour. Different philosophical and practical approaches to this have emerged. On the one hand, there is a view that, with health-care budgets set centrally, decision-making bodies within the system can iterate, from observation of a series of previous decisions, towards the value of a QALY, thus searching for such a value. Alternatively, and more consistent with the approach taken in other public sectors, individual members of the public are surveyed with the aim of directly eliciting a preference-based – also known as a willingness-to-pay-based (WTP-based) – value of a QALY. While the former is based on supply-side factors and the latter on demand, both in fact suffer from informational deficiencies. Sole reliance on either would necessitate an acceptance or accommodation of chronic inefficiencies in health-care resource allocation. On the basis of this observation, this paper makes the case that in order to approach optimal decision making in health-care provision, a framework incorporating and thus, to a degree, reconciling these two approaches is to be preferred.

[1]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[2]  Dorte Gyrd-Hansen,et al.  Estimating a WTP-based value of a QALY: the 'chained' approach. , 2013, Social science & medicine.

[3]  I. Bateman,et al.  Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. , 2010, Health technology assessment.

[4]  Richard D. Smith,et al.  Contingent valuation: what needs to be done? , 2010, Health Economics, Policy and Law.

[5]  C. Donaldson,et al.  The impact of information on patient preferences in different delivery patterns: a contingent valuation study of prescription versus OTC drugs. , 2009, Health policy.

[6]  M. Buxton,et al.  Searching for cost effectiveness thresholds in the NHS. , 2009, Health policy.

[7]  G. Loomes,et al.  Trying to estimate a monetary value for the QALY. , 2009, Journal of health economics.

[8]  N. Rice,et al.  Does health care spending improve health outcomes? Evidence from English programme budgeting data. , 2008, Journal of health economics.

[9]  Michael Jones-Lee,et al.  Valuing lives equally: Defensible premise or unwarranted compromise? , 2008 .

[10]  A. Tsuchiya,et al.  The relative societal value of health gains to different beneficiaries: a summary , 2008 .

[11]  C. Donaldson,et al.  Managing to manage healthcare resources in the English NHS? What can health economics teach? What can health economics learn? , 2007, Health policy.

[12]  Karl Claxton,et al.  Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence , 2007, Journal of health services research & policy.

[13]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[14]  C E Phelps,et al.  On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.

[15]  Anthony J. Culyer,et al.  The NICE Cost-Effectiveness Threshold , 2012, PharmacoEconomics.

[16]  National Institute for Health and Clinical Excellence , 2010 .

[17]  A. Culyer,et al.  Pharmacoeconomics 2008; 26 (9): 733-744 , 2008 .

[18]  Cam Donaldson,et al.  The new myth: the social value of the QALY. , 2008, PharmacoEconomics.

[19]  A. Holly,et al.  The impact of information on patient preferences in different delivery patterns (prescription versus OTC drugs) , 2005 .

[20]  A. Gafni,et al.  The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. , 2002, Health economics.